United States Epilepsy Therapeutics Market Report 2017

August 2017 | 95 pages | ID: UEDA29B00DCEN
QYResearch

Abstracts

In this report, the United States Epilepsy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Epilepsy Therapeutics in these regions, from 2012 to 2022 (forecast).

United States Epilepsy Therapeutics market competition by top manufacturers/players, with Epilepsy Therapeutics sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Abbott Laboratories
• GlaxoSmithKline plc
• Cephalon
• Johnson & Johnson
• Pfizer
• Novartis AG
• Sunovion Pharmaceuticals
• Valeant Pharmaceuticals International
• Sanofi S.A.
• Shire

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• First Generation
• Second Generation

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Epilepsy Therapeutics for each application, including

• Hospital
• Pharmacy
• Clinic

Contents

United States Epilepsy Therapeutics Market Report 2017

1 EPILEPSY THERAPEUTICS OVERVIEW

1.1 Product Overview and Scope of Epilepsy Therapeutics
1.2 Classification of Epilepsy Therapeutics by Product Category
  1.2.1 United States Epilepsy Therapeutics Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Epilepsy Therapeutics Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 First Generation
  1.2.4 Second Generation
1.3 United States Epilepsy Therapeutics Market by Application/End Users
  1.3.1 United States Epilepsy Therapeutics Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital
  1.3.3 Pharmacy
  1.3.4 Clinic
1.4 United States Epilepsy Therapeutics Market by Region
  1.4.1 United States Epilepsy Therapeutics Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Epilepsy Therapeutics Status and Prospect (2012-2022)
  1.4.3 Southwest Epilepsy Therapeutics Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Epilepsy Therapeutics Status and Prospect (2012-2022)
  1.4.5 New England Epilepsy Therapeutics Status and Prospect (2012-2022)
  1.4.6 The South Epilepsy Therapeutics Status and Prospect (2012-2022)
  1.4.7 The Midwest Epilepsy Therapeutics Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Epilepsy Therapeutics (2012-2022)
  1.5.1 United States Epilepsy Therapeutics Sales and Growth Rate (2012-2022)
  1.5.2 United States Epilepsy Therapeutics Revenue and Growth Rate (2012-2022)

2 UNITED STATES EPILEPSY THERAPEUTICS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Epilepsy Therapeutics Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Epilepsy Therapeutics Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Epilepsy Therapeutics Average Price by Players/Suppliers (2012-2017)
2.4 United States Epilepsy Therapeutics Market Competitive Situation and Trends
  2.4.1 United States Epilepsy Therapeutics Market Concentration Rate
  2.4.2 United States Epilepsy Therapeutics Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Epilepsy Therapeutics Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES EPILEPSY THERAPEUTICS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Epilepsy Therapeutics Sales and Market Share by Region (2012-2017)
3.2 United States Epilepsy Therapeutics Revenue and Market Share by Region (2012-2017)
3.3 United States Epilepsy Therapeutics Price by Region (2012-2017)

4 UNITED STATES EPILEPSY THERAPEUTICS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Epilepsy Therapeutics Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Epilepsy Therapeutics Revenue and Market Share by Type (2012-2017)
4.3 United States Epilepsy Therapeutics Price by Type (2012-2017)
4.4 United States Epilepsy Therapeutics Sales Growth Rate by Type (2012-2017)

5 UNITED STATES EPILEPSY THERAPEUTICS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Epilepsy Therapeutics Sales and Market Share by Application (2012-2017)
5.2 United States Epilepsy Therapeutics Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES EPILEPSY THERAPEUTICS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Abbott Laboratories
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Epilepsy Therapeutics Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Abbott Laboratories Epilepsy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 GlaxoSmithKline plc
  6.2.2 Epilepsy Therapeutics Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 GlaxoSmithKline plc Epilepsy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Cephalon
  6.3.2 Epilepsy Therapeutics Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Cephalon Epilepsy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Johnson & Johnson
  6.4.2 Epilepsy Therapeutics Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Johnson & Johnson Epilepsy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer
  6.5.2 Epilepsy Therapeutics Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer Epilepsy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Novartis AG
  6.6.2 Epilepsy Therapeutics Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Novartis AG Epilepsy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Sunovion Pharmaceuticals
  6.7.2 Epilepsy Therapeutics Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Sunovion Pharmaceuticals Epilepsy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Valeant Pharmaceuticals International
  6.8.2 Epilepsy Therapeutics Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Valeant Pharmaceuticals International Epilepsy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Sanofi S.A.
  6.9.2 Epilepsy Therapeutics Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Sanofi S.A. Epilepsy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Shire
  6.10.2 Epilepsy Therapeutics Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Shire Epilepsy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview

7 EPILEPSY THERAPEUTICS MANUFACTURING COST ANALYSIS

7.1 Epilepsy Therapeutics Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Epilepsy Therapeutics

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Epilepsy Therapeutics Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Epilepsy Therapeutics Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES EPILEPSY THERAPEUTICS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Epilepsy Therapeutics Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Epilepsy Therapeutics Sales Volume Forecast by Type (2017-2022)
11.3 United States Epilepsy Therapeutics Sales Volume Forecast by Application (2017-2022)
11.4 United States Epilepsy Therapeutics Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Epilepsy Therapeutics
Figure United States Epilepsy Therapeutics Market Size (K Units) by Type (2012-2022)
Figure United States Epilepsy Therapeutics Sales Volume Market Share by Type (Product Category) in 2016
Figure First Generation Product Picture
Figure Second Generation Product Picture
Figure United States Epilepsy Therapeutics Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Epilepsy Therapeutics by Application in 2016
Figure Hospital Examples
Figure Pharmacy Examples
Figure Clinic Examples
Figure United States Epilepsy Therapeutics Market Size (Million USD) by Region (2012-2022)
Figure The West Epilepsy Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Epilepsy Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Epilepsy Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Epilepsy Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Epilepsy Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Epilepsy Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Epilepsy Therapeutics Sales (K Units) and Growth Rate (2012-2022)
Figure United States Epilepsy Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Epilepsy Therapeutics Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Epilepsy Therapeutics Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Epilepsy Therapeutics Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Epilepsy Therapeutics Sales Share by Players/Suppliers
Figure 2017 United States Epilepsy Therapeutics Sales Share by Players/Suppliers
Figure United States Epilepsy Therapeutics Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Epilepsy Therapeutics Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Epilepsy Therapeutics Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Epilepsy Therapeutics Revenue Share by Players/Suppliers
Figure 2017 United States Epilepsy Therapeutics Revenue Share by Players/Suppliers
Table United States Market Epilepsy Therapeutics Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Epilepsy Therapeutics Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Epilepsy Therapeutics Market Share of Top 3 Players/Suppliers
Figure United States Epilepsy Therapeutics Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Epilepsy Therapeutics Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Epilepsy Therapeutics Product Category
Table United States Epilepsy Therapeutics Sales (K Units) by Region (2012-2017)
Table United States Epilepsy Therapeutics Sales Share by Region (2012-2017)
Figure United States Epilepsy Therapeutics Sales Share by Region (2012-2017)
Figure United States Epilepsy Therapeutics Sales Market Share by Region in 2016
Table United States Epilepsy Therapeutics Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Epilepsy Therapeutics Revenue Share by Region (2012-2017)
Figure United States Epilepsy Therapeutics Revenue Market Share by Region (2012-2017)
Figure United States Epilepsy Therapeutics Revenue Market Share by Region in 2016
Table United States Epilepsy Therapeutics Price (USD/Unit) by Region (2012-2017)
Table United States Epilepsy Therapeutics Sales (K Units) by Type (2012-2017)
Table United States Epilepsy Therapeutics Sales Share by Type (2012-2017)
Figure United States Epilepsy Therapeutics Sales Share by Type (2012-2017)
Figure United States Epilepsy Therapeutics Sales Market Share by Type in 2016
Table United States Epilepsy Therapeutics Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Epilepsy Therapeutics Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Epilepsy Therapeutics by Type (2012-2017)
Figure Revenue Market Share of Epilepsy Therapeutics by Type in 2016
Table United States Epilepsy Therapeutics Price (USD/Unit) by Types (2012-2017)
Figure United States Epilepsy Therapeutics Sales Growth Rate by Type (2012-2017)
Table United States Epilepsy Therapeutics Sales (K Units) by Application (2012-2017)
Table United States Epilepsy Therapeutics Sales Market Share by Application (2012-2017)
Figure United States Epilepsy Therapeutics Sales Market Share by Application (2012-2017)
Figure United States Epilepsy Therapeutics Sales Market Share by Application in 2016
Table United States Epilepsy Therapeutics Sales Growth Rate by Application (2012-2017)
Figure United States Epilepsy Therapeutics Sales Growth Rate by Application (2012-2017)
Table Abbott Laboratories Basic Information List
Table Abbott Laboratories Epilepsy Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Abbott Laboratories Epilepsy Therapeutics Sales Growth Rate (2012-2017)
Figure Abbott Laboratories Epilepsy Therapeutics Sales Market Share in United States (2012-2017)
Figure Abbott Laboratories Epilepsy Therapeutics Revenue Market Share in United States (2012-2017)
Table GlaxoSmithKline plc Basic Information List
Table GlaxoSmithKline plc Epilepsy Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure GlaxoSmithKline plc Epilepsy Therapeutics Sales Growth Rate (2012-2017)
Figure GlaxoSmithKline plc Epilepsy Therapeutics Sales Market Share in United States (2012-2017)
Figure GlaxoSmithKline plc Epilepsy Therapeutics Revenue Market Share in United States (2012-2017)
Table Cephalon Basic Information List
Table Cephalon Epilepsy Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Cephalon Epilepsy Therapeutics Sales Growth Rate (2012-2017)
Figure Cephalon Epilepsy Therapeutics Sales Market Share in United States (2012-2017)
Figure Cephalon Epilepsy Therapeutics Revenue Market Share in United States (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Epilepsy Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Johnson & Johnson Epilepsy Therapeutics Sales Growth Rate (2012-2017)
Figure Johnson & Johnson Epilepsy Therapeutics Sales Market Share in United States (2012-2017)
Figure Johnson & Johnson Epilepsy Therapeutics Revenue Market Share in United States (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Epilepsy Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer Epilepsy Therapeutics Sales Growth Rate (2012-2017)
Figure Pfizer Epilepsy Therapeutics Sales Market Share in United States (2012-2017)
Figure Pfizer Epilepsy Therapeutics Revenue Market Share in United States (2012-2017)
Table Novartis AG Basic Information List
Table Novartis AG Epilepsy Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis AG Epilepsy Therapeutics Sales Growth Rate (2012-2017)
Figure Novartis AG Epilepsy Therapeutics Sales Market Share in United States (2012-2017)
Figure Novartis AG Epilepsy Therapeutics Revenue Market Share in United States (2012-2017)
Table Sunovion Pharmaceuticals Basic Information List
Table Sunovion Pharmaceuticals Epilepsy Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sunovion Pharmaceuticals Epilepsy Therapeutics Sales Growth Rate (2012-2017)
Figure Sunovion Pharmaceuticals Epilepsy Therapeutics Sales Market Share in United States (2012-2017)
Figure Sunovion Pharmaceuticals Epilepsy Therapeutics Revenue Market Share in United States (2012-2017)
Table Valeant Pharmaceuticals International Basic Information List
Table Valeant Pharmaceuticals International Epilepsy Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Valeant Pharmaceuticals International Epilepsy Therapeutics Sales Growth Rate (2012-2017)
Figure Valeant Pharmaceuticals International Epilepsy Therapeutics Sales Market Share in United States (2012-2017)
Figure Valeant Pharmaceuticals International Epilepsy Therapeutics Revenue Market Share in United States (2012-2017)
Table Sanofi S.A. Basic Information List
Table Sanofi S.A. Epilepsy Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanofi S.A. Epilepsy Therapeutics Sales Growth Rate (2012-2017)
Figure Sanofi S.A. Epilepsy Therapeutics Sales Market Share in United States (2012-2017)
Figure Sanofi S.A. Epilepsy Therapeutics Revenue Market Share in United States (2012-2017)
Table Shire Basic Information List
Table Shire Epilepsy Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Shire Epilepsy Therapeutics Sales Growth Rate (2012-2017)
Figure Shire Epilepsy Therapeutics Sales Market Share in United States (2012-2017)
Figure Shire Epilepsy Therapeutics Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Epilepsy Therapeutics
Figure Manufacturing Process Analysis of Epilepsy Therapeutics
Figure Epilepsy Therapeutics Industrial Chain Analysis
Table Raw Materials Sources of Epilepsy Therapeutics Major Players/Suppliers in 2016
Table Major Buyers of Epilepsy Therapeutics
Table Distributors/Traders List
Figure United States Epilepsy Therapeutics Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Epilepsy Therapeutics Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Epilepsy Therapeutics Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Epilepsy Therapeutics Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Epilepsy Therapeutics Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Epilepsy Therapeutics Sales Volume (K Units) Forecast by Type in 2022
Table United States Epilepsy Therapeutics Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Epilepsy Therapeutics Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Epilepsy Therapeutics Sales Volume (K Units) Forecast by Application in 2022
Table United States Epilepsy Therapeutics Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Epilepsy Therapeutics Sales Volume Share Forecast by Region (2017-2022)
Figure United States Epilepsy Therapeutics Sales Volume Share Forecast by Region (2017-2022)
Figure United States Epilepsy Therapeutics Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources